PMID- 30142405
OWN - NLM
STAT- MEDLINE
DCOM- 20190508
LR  - 20190508
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 121
DP  - 2018 Nov
TI  - The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical 
      Prostatectomy Independent of PTEN Status.
PG  - 132-138
LID - S0090-4295(18)30764-7 [pii]
LID - 10.1016/j.urology.2018.07.018 [doi]
AB  - OBJECTIVE: To compare the ability of loss of phosphatase and tensin homolog 
      (PTEN) and Genomic prostate score assay (GPS) in predicting the 
      biochemical-recurrence (BCR) and clinical-recurrence (CR) after radical 
      prostatectomy (RP) for clinically localized prostate cancer (PCa). METHODS: Three 
      hundred seventy seven patients with and without CR were retrospectively selected 
      by stratified cohort sampling design from RP database. PTEN status (by 
      immunohistochemistry [IHC] and fluorescence in situ hybridization [FISH]) and GPS 
      results were determined for RP specimens. BCR was defined as Prostate Specific 
      Antigen (PSA) >/= 0.2 ng/mL or initiation of salvage therapy for a rising PSA. CR 
      was defined as local recurrence and/or distant metastases. RESULTS: Baseline mean 
      age, PSA, and GPS score for the cohort were 61.1 years, 8 ng/dL, and 32.8. PTEN 
      loss was noted in 38% patients by FISH and 25% by IHC. The concordance between 
      FISH and IHC for PTEN loss was 66% (Kappa coefficient 0.278; P < .001). On 
      univariable analysis, loss of PTEN by FISH or IHC was associated with BCR and CR 
      (P < .05). However, after adjusting for GPS results, PTEN loss was not a 
      significant predictor for CR or BCR (P > .1). The GPS result remained strongly 
      associated with CR and BCR after adjusting for PTEN status (P < .001). PTEN 
      status and GPS results only weakly correlated. GPS was widely distributed 
      regardless of PTEN status indicating the biological heterogeneity of PCa even in 
      PTEN-deficient cases. CONCLUSION: GPS is a significant predictor of aggressive 
      PCa, independent of PTEN status. After adjustment for GPS results, PTEN was not 
      independently associated with recurrence for PCa.
CI  - Copyright (c) 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Magi-Galluzzi, Cristina
AU  - Magi-Galluzzi C
AD  - Department of Urology, Glickman Urology and Kidney Institute, Cleveland Clinic, 
      Cleveland, OH; Robert J. Tomsich Pathology and Laboratory Medicine Institute, 
      Cleveland Clinic, Cleveland, OH.
FAU - Isharwal, Sudhir
AU  - Isharwal S
AD  - Department of Urology, Glickman Urology and Kidney Institute, Cleveland Clinic, 
      Cleveland, OH.
FAU - Falzarano, Sara M
AU  - Falzarano SM
AD  - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
      Cleveland, OH.
FAU - Tsiatis, Athanasios
AU  - Tsiatis A
AD  - Genomic Health, Inc., Redwood City, CA.
FAU - Dee, Anne
AU  - Dee A
AD  - Genomic Health, Inc., Redwood City, CA.
FAU - Maddala, Tara
AU  - Maddala T
AD  - Genomic Health, Inc., Redwood City, CA.
FAU - Knezevic, Dejan
AU  - Knezevic D
AD  - Genomic Health, Inc., Redwood City, CA.
FAU - Febbo, Phillip G
AU  - Febbo PG
AD  - Genomic Health, Inc., Redwood City, CA.
FAU - Lawrence, Jeffrey
AU  - Lawrence J
AD  - Genomic Health, Inc., Redwood City, CA.
FAU - Klein, Eric A
AU  - Klein EA
AD  - Department of Urology, Glickman Urology and Kidney Institute, Cleveland Clinic, 
      Cleveland, OH. Electronic address: kleine@ccf.org.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180822
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Gene Expression Profiling/methods
MH  - Genomics/*methods
MH  - Humans
MH  - Lymphatic Metastasis/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*diagnosis
MH  - Neoplasm Staging
MH  - PTEN Phosphohydrolase/*analysis
MH  - Prognosis
MH  - Prostate-Specific Antigen/analysis
MH  - Prostatectomy/*adverse effects/methods
MH  - *Prostatic Neoplasms/genetics/pathology/surgery
MH  - Research Design
MH  - Risk Assessment/methods
MH  - Salvage Therapy/methods
EDAT- 2018/08/25 06:00
MHDA- 2019/05/09 06:00
CRDT- 2018/08/25 06:00
PHST- 2018/03/06 00:00 [received]
PHST- 2018/06/17 00:00 [revised]
PHST- 2018/07/16 00:00 [accepted]
PHST- 2018/08/25 06:00 [pubmed]
PHST- 2019/05/09 06:00 [medline]
PHST- 2018/08/25 06:00 [entrez]
AID - S0090-4295(18)30764-7 [pii]
AID - 10.1016/j.urology.2018.07.018 [doi]
PST - ppublish
SO  - Urology. 2018 Nov;121:132-138. doi: 10.1016/j.urology.2018.07.018. Epub 2018 Aug 
      22.